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Re: Development of an Instrument to Assess the Health Related
Quality of Life of Kidney Stone Formers
K. L. Penniston and S. Y. Nakada
J Urol 2013; 189: 921e930.
To the Editor: We read this article with great interest and congratulate the authors on their
work. There has been a need for a disease specific health related quality of life (HRQoL)
assessment tool in the field of urolithiasis for some time. Urinary tract calculi can be extremely
painful and represent the second most costly disease in urology.1,2 The stone patient experience
is something that has not been fully explored, and the authors have attempted to elucidate
many important symptoms that clinicians may have ignored or not thought of in the past.
There is wide variation in symptoms and HRQoL impact, with stones ranging from completely
asymptomatic to those causing short-lived but acute colic. In addition, the various in-
terventions to treat stones add a level of complexity to the measurement of HRQoL in this
group of patients. Hence, it is important during the creation of any new HRQoL instrument
that the most up-to-date techniques and methodologies be used, that the methodology be clear
for all to examine so that it can be evaluated fully and its validity judged, and that it stand the
test of time.3
We believe that the item generation methodology needs further explanation. The authors
state that they asked health care providers for their views during interviews and focus
groups, and this approach surely influenced the study as a whole. This action moves the
study away from a patient centric viewpoint, which is the cornerstone of qualitative research
(it appears that the themes for the patient interviews were already generated based on the
provider views). Similarly, were the patient groups inclusive enough to cover all stone groups,
such as patients without calcium or metabolic disorders? Acute stone episodes and thera-
peutic interventions appear to be excluded. It would be useful to review the itinerary and
transcripts of these interviews and examine direct quotes/excerpts used to develop the
methodology. It is unclear which excerpts of the hierarchy of ideas were used and whether
the correct content was captured. There is also no mention of whether the content of the
interviews was analyzed manually or electronically, and if electronically (which is standard
practice), which software platform was used.
While it is clear that there are 3 domains identified, it is unclear how each domain is weighted
and, therefore, how they contribute to the final score. Is it possible that the item selection and
reduction results were influenced by issues surrounding qualitative research? There is no clear
evidence of reproducibility of the methods used to collect the data, for example test-retest
reliability information. Content validity is not mentioned. Was the instrument validated by
the target population or an expert panel? There is also no mention of the responsiveness of the
instrument, eg responses in an asymptomatic stone population or comparison with patients
undergoing interventions, and whether this was tested. Finally, the new generation of quality of
life instruments should be designed to be capable of generating utility values for use in economic
evaluations.4,5
We have been unable to obtain a copy of the instrument anywhere in the article or in any
other published source or contact the authors. We believe that to fully evaluate this instrument
and, therefore, assess its clinical relevance and usefulness in practice, it would be useful if the
data were freely available for interested researchers to review to further advance this important
topic of scientific research.
Respectfully,
Aditya Raja, Claire O’Neill and Hrishi B. Joshi
Department of Urology
University Hospital of Wales
and
280 LETTERS TO THE EDITOR/ERRATA
Sam Salek
Centre for Socioeconomic Research
Cardiff University
Cardiff, Wales
United Kingdom
1. Bergman J, Gore JL, Singer JS et al: Readability of health related
quality of life instruments in urology. J Urol 2010; 183: 1977.
2. Rabah DM, Alomar M, Binsaleh S et al: Health related quality of life in
ureteral stone patients: post-ureterolithiasis. Urol Res 2011; 39: 385.
3. Aaronson N, Alonso J, Burnam A et al: Assessing health status and
quality-of-life instruments: attributes and review criteria. Qual Life
Res 2002; 11: 193.
4. Joshi HB, Stainthorpe A, MacDonagh RP et al: Indwelling ureteral
stents: evaluation of symptoms, quality of life and utility. J Urol 2003;
169: 1065.
5. Matlaga BR, Jansen JP, Meckley LM et al: Economic outcomes
of treatment for ureteral and renal stones: a systematic literature
review. J Urol 2012; 188: 449.
Reply by Authors: Regarding the methodology for our development of the WSQ (Wisconsin
Stone-QOL), we followed the 4 iterative steps outlined by the U.S. Food and Drug Administra-
tion for development of patient reported outcome measures.1 We included as much detail as
space allowed in our initial published report. Table 2 in the article lists the 65 discrete items that
emanated from patient only discussions, which were grouped within 6 general themes identified
in our manual coding. Table 4 in the article actually lists all 28 items, although not in the specific
wording of the final WSQ. While electronic analyses using specifically designed software plat-
forms appear useful, they need not be used in all situations. Computer assisted analysis, which
requires manual coding, does not in and of itself ensure that the correct content is captured, nor
the validity of the approach and/or final product.
Content validity was appraised in step 2, after patients completed a reduced item pilot survey
and provided general feedback about content as well as opinions about 2 different item response
formats. With refinement based on these comments and those of the urologists, the final ques-
tionnaire was developed. As noted in our article, “Further testing is needed to assess test-retest
reliability, concurrent validity. and construct validity,” measurable instrument properties that
are outlined in step 3 of the Food and Drug Administration guidelines. We are pleased to report
that these tests, as well as others, are currently under way.
Finally, as to therapeutic interventions, an entire theme composed of 16 separate items (table
2 in article) was generated from patient comments and is represented on the final WSQ.
Regarding economic impact, this issue did not emerge as a major theme in our patient discus-
sions, perhaps owing to unique factors within our patient population. As our instrument is tested
in alternate settings, this and other factors may emerge as important enough to be added as a
modification to the WSQ.
1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research: Guidance for industry: patient-reported outcome
measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
Re: Are Osteotomies Necessary for Bladder Exstrophy Closure?
J. G. Borer
J Urol 2014; 191: 13e14.
To the Editor: In this article Borer broaches the continuing debate of the importance of pelvic
osteotomy for primary bladder exstrophy closure. The bulk of his argument supporting the
notion that osteotomy is not important is derived from successful closure by Mushtaq et al of 95%
of bladder exstrophy cases (70 of 74) without the use of osteotomy.1 It is noteworthy that
Mushtaq et al omitted any description of the width of the pubic diastasis of the study population,
an important variable. We agree that newborn closure is feasible and easily accomplished if the
bladder template is of good quality, the pubic diastasis is not excessive (less than 4 cm) and the
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